Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
30 août 2018 16h07 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
The American Health Council Appoints Nicholas Avitabile, MD to Board of Physicians
17 août 2018 08h00 HE
|
American Health Council
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- The American Health Council appointed Nicholas Avitabile, MD to its Board of Physicians for his outstanding contributions to the medical field. An...
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
20 juil. 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering
17 juil. 2018 18h55 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
21 juin 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Esoteric Testing Market will retain 9.4% CAGR to beat $35 billion by 2024: Global Market Insights, Inc.
09 mai 2018 05h13 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, May 09, 2018 (GLOBE NEWSWIRE) -- Esoteric Testing Market is expected to surpass USD 35 billion by 2024; according to a new research report by Global Market Insights....
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
13 mars 2018 14h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
12 mars 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an...
Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
07 mars 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
04 janv. 2018 09h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...